1[1]Mokrzychi MH,Kaplan AA.Therapeutic plasma exchange:complications and management.Am J Kidney Dis,1994,23:817
2[2]Bandarenko N,Brecger ME.United States Thrombotic Thromboeytopenic Purpura Apheresis Study Group(USA TTP SAG):Multicenter retrospective analysis of current efficacy of therapeutic plasma exchange.J Clin Apheresis,1998,13:133
3[3]Mcleod BC,Sniecinski I,Ciavarella D,et al.Frequency of immediate adverse effects associated with therapeutic apheresis.Transfusion,1999,39:282
4[4]Gilcher RO,Strauss RG,Ciavarella D,et al.Management of renal disorders.J Clin Apheresis,1993,8:258
5[5]Berrouschot J,Baumman I,Kalischewski P,et al.Therapy of myesthenic crisis.Crit Care Med,1997,25:1228
6[6]Ciavarella D,Wuest D,Strauss RG,et al.Management of neurologic disorders.J Clin Apheresis,1993,8:242
7[7]Kasprisin DO,Strauss RG,Ciavalrlla D,et al.Management of metabolic and miscellaneous disorders.J Clin Apheresis,1993,8:231
8[8]Kiss JE,Berman D,Van TD,et al.Effective removal of copper by plasma exchange in fulminant Wilson' s disease.Transfusion,1998,38:327
9[9]Palmisano J,Agraharkar M,Kaplan AA,et al.Successful treatment of cisplatin induced hemolytic uremic syndrome with therapeutic plasma exchange.Am J Kidney Dis,1998,32:314
10[10]Kes P.Therapeutic plasma exchange in severe sepsis or septic shock.Acta Med Croatica,1998,52:127
